Fluoxetine cyp3a4 inhibitor

If a strong CYP3A4 inhibitor and strong CYP2D6 inhibitor are coadministered or a known CYP2D6 poor metabolizer is receiving a concomitant strong CYP3A4 inhibitor, the ABILIFY dose should be reduced to one-quarter (25%) of the usual dose, . Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase (2.6 7.1) (2.6 12.3)

Aripiprazole may interact with strong CYP3A4 inhibitors (such as itraconazole, clarithromycin) or CYP2D6 inhibitors (such as fluoxetine, paroxetine).

fluoxetine is a CYP1C9 substrate and a mechanism-based inhibitor of CYp2C19 Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its

have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate

Fluoxetine, a strong CYP2D6 inhibitor, increases the plasma concentration of risperidone, Aripiprazole, a CYP2D6 and CYP3A4 substrate: Risperidone

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate

by TOM LYNCH 2024 Cited by 1423Diltiazem (Cardizem), verapamil, CYP3A4 inhibitor, Prednisone ; Fluoxetine (Prozac), paroxetine (Paxil), CYP2D6 inhibitor, Risperidone (

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate